# 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

> **NCT06926998** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Gynecological Malignancies

## Interventions

- **DRUG:** 9MW2821+other anticancer therapy

## Key facts

- **NCT ID:** NCT06926998
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926998, "9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06926998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*